Logo Logo
Hilfe
Hilfe
Switch Language to English

Wildner, Gerhild (2021): Tumors, tumor therapies, autoimmunity and the eye. In: Autoimmunity Reviews, Bd. 20, Nr. 9, 102892

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

The eye as an immune privileged organ is mostly spared from (auto)immune attacks. Intraocular inflammation like autoimmune uveitis is a rare event. Nevertheless, tumor-related destructive autoimmune responses can affect the eye, as observed in the case of cancer-associated retinopathy (CAR), an autoantibody-mediated destruction of retinal cells induced by the ectopic expression of ocular antigens by peripheral tumors. The new tumor therapies targeting immune checkpoints to enhance anti-tumor responses can also induce autoimmune responses and result in autoimmune diseases even in immune privileged organs like the eyes. Even MEK/BRAF-inhibitor therapies using small molecules to block tumor-specific signal transduction molecules have turned out to not just inhibit tumor growth and survival and render tumors more susceptible for immune recognition, but to have additional toxic effects on non-dividing retinal cells, destroying and making them potential targets of autoimmunity.

Dokument bearbeiten Dokument bearbeiten